News | July 16, 2012

Cardiosolutions Inc. Gathers Major Investment from Sorin Group

Investment to fund development of Cardiosolutions percutaneous technology for mitral regurgitation

July 16, 2012 — Cardiosolutions Inc., an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation, today announced it has received a minority investment from Sorin Group. Sorin is a global medical device company and develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. 

Cardiosolutions' technology consists of a proprietary catheter delivery system and an implant, the Mitra-Spacer. This implant is designed to fill the void created by a dilated annulus or deteriorating valve mechanism providing a sealing surface for the leaflets of the mitral valve, thus reducing the degree of mitral regurgitation in patients.

This technology represents a less invasive, percutaneous solution for patients who suffer from moderate to severe mitral regurgitation, including a portion of those who have congestive heart failure. Today two to three percent of the world's population suffers from mitral regurgitation and approximately 2.3 million patients in the United States and Europe suffer from severe mitral regurgitation. Every year approximately 500,000 new patients are diagnosed with this disease, of which more than 80 percent are untreated. A substantial group of patients have no option because they are too sick to survive the surgery and many others delay treatment because they have only moderate symptoms. 

Sorin's $8 million investment will finance on-going product development and clinical testing of this technology. Under the terms of the agreement, Sorin also has an option to acquire the company in the future. Sorin Group joins STD Med and BioVentures Investors as an investor in Cardiosolutions.

For more information: www.sorin.com

Related Content

Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
The Edwards Lifesciences Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May.

The Edwards Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May, becoming the first transcatheter tricuspid repair device to be approved in the world.

Feature | Heart Valve Technology | August 21, 2018 | Jeff Zagoudis
The tricuspid valve has been dubbed “the forgotten valve” by many practitioners in the interventional cardiology spac
Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Overlay Init